Article

Hepatitis B Virus X protein is essential to initiate and maintain virus replication after infection

Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Trogerstrasse, 30, 81675 Munich, Germany.
Journal of Hepatology (Impact Factor: 11.34). 03/2011; 55(5):996-1003. DOI: 10.1016/j.jhep.2011.02.015
Source: PubMed

ABSTRACT

The molecular biology of hepatitis B virus (HBV) has been extensively studied but the exact role of the hepatitis B X protein (HBx) in the context of natural HBV infections remains unknown.
Primary human hepatocytes and differentiated HepaRG cells allowing conditional trans complementation of HBx were infected with wild type (HBV(wt)) or HBx deficient (HBV(x-)) HBV particles and establishment of HBV replication was followed.
We observed that cells inoculated with HBx-deficient HBV particles (HBV(x-)) did not lead to productive HBV infection contrary to cells inoculated with wild type HBV particles (HBV(wt)). Although equal amounts of nuclear covalently closed circular HBV-DNA (cccDNA) demonstrated comparable uptake and nuclear import, active transcription was only observed from HBV(wt) genomes. Trans-complementation of HBx was able to rescue transcription from the HBV(x-) genome and led to antigen and virion secretion, even weeks after infection. Constant expression of HBx was necessary to maintain HBV antigen expression and replication. Finally, we demonstrated that HBx is not packaged into virions during assembly but is expressed after infection within the new host cell to allow epigenetic control of HBV transcription from cccDNA.
Our results demonstrate that HBx is required to initiate and maintain HBV replication and highlight HBx as the key regulator during the natural infection process.

1 Follower
 · 
25 Reads
    • "HepaRG cells differentiated and cultured as described[11]. Protein-prime/MVA-boost vaccination is highly immunogenic. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Therapeutic vaccination is a novel treatment approach for chronic hepatitis B, but only had limited success so far. We hypothesized that optimized vaccination schemes have increased immunogenicity, and aimed at increasing therapeutic hepatitis B vaccine efficacy. Methods: Modified Vaccinia virus Ankara (MVA) expressing hepatitis B virus (HBV) antigens was used to boost protein-prime vaccinations in wildtype and HBV-transgenic (HBVtg) mice. Results: Protein-prime/MVA-boost vaccination was able to overcome HBV-specific tolerance in HBVtg mice with low and medium but not with high antigenemia. HBV-specific antibody titers, CD8+ T-cell frequencies and polyfunctionality inversely correlated with HBV antigen levels. However, optimization of the adjuvant formulation, increasing the level of antigen expression and utilization of HBsAg of heterologous subtype induced HBV-specific CD8+ and CD4+ T-cells and neutralizing antibodies even in high-antigenemic HBVtg mice. Conclusions: Our results indicate that high HBV antigen levels limit the immunological responsiveness to therapeutic vaccination but optimization of the vaccine formulation can overcome tolerance even in the presence of high antigenemia. These findings have important implications for the development of future therapeutic hepatitis B vaccination strategies and potentially also for the stratification of chronic hepatitis B patients for therapeutic vaccination.
    No preview · Article · Jan 2016 · Vaccine
  • Source
    • "HBV inoculum was either concentrated from filtered HepG2.2.15 (wild-type virus) or K6 (HBx negative virus) [25] supernatants by polyethylene glycol (PEG) precipitation as previously described [22], or partially purified by heparin chromatography [26], then concentrated using centrifugal filters devices (Amicon Ultracel 100K, Millipore). A mock ''HBV-negative'' inoculum (mock control) was generated by depletion of Dane particles, HBsAg and HBeAg using centrifugal filters devices (Amicon Ultracel 10K, Millipore). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The outcome of Hepatitis B virus infection may be influenced by early interactions between the virus and hepatocyte innate immune responses. To date, the study of such interactions during the very early step of infection has not been adequately investigated. We used the HepaRG cell line, as well as primary human hepatocytes to analyze, within 24 hours of exposure to HBV, either delivered by a physiologic route or baculovirus vector (Bac-HBV), the early modulation of the expression of selected antiviral/pro-inflammatory cytokines and interferon-stimulated-genes. Experiments were also performed in presence or absence of innate receptor agonists to investigate early HBV-induced blockade of innate responses. We show that hepatocytes themselves could detect HBV, and express innate genes when exposed to either HBV virions or Bac-HBV. Whereas Bac-HBV triggered a strong antiviral cytokine secretion followed by the clearance of replicative intermediates, a physiologic HBV exposure led to an abortive response. The early inhibition of innate response by HBV was mainly evidenced on TLR3 and RIG-I/MDA5 signaling pathways upon engagement with exogenous agonist, leading to a decreased expression of several pro-inflammatory and antiviral cytokine genes. Finally, we demonstrate that this early inhibition of dsRNA-mediated response is due to factor(s) present in the HBV inoculum, but not being HBsAg or HBeAg themselves, and does not require de novo viral protein synthesis and replication. Our data provide strong evidence that HBV viral particles themselves can readily inhibit host innate immune responses upon virion/cell interactions, and may explain, at least partially, the "stealthy" character of HBV. Copyright © 2015. Published by Elsevier B.V.
    Full-text · Article · Jul 2015 · Journal of Hepatology
    • "Thus, cccDNA is persistent throughout the cycle of infectivity. cccDNA is decorated with the usual proteins of euchromatin with the addition of two HBV proteins: X and Cp (Belloni et al., 2009; Bock et al., 2001; Buendia and Neuveut, 2015; Ducroux et al., 2014; Fallot et al., 2012; Levrero et al., 2009; Lucifora et al., 2011; Pollicino et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis B Virus (HBV) is a small virus whose genome has only four open reading frames. We argue that the simplicity of the virion correlates with a complexity of functions for viral proteins. We focus on the HBV core protein (Cp), a small (183 residue) protein that self-assembles to form the viral capsid. However, its functions are a little more complicated than that. In an infected cell Cp modulates every step of the viral lifecycle. Cp is bound to nuclear viral DNA and affects its epigenetics. Cp correlates with RNA specificity. Cp assembles specifically on a reverse transcriptase-viral RNA complex or, apparently, nothing at all. Indeed Cp has been one of the model systems for investigation of virus self-assembly. Cp participates in regulation of reverse transcription. Cp signals completion of reverse transcription to support virus secretion. Cp carries both nuclear localization signals and HBV surface antigen (HBsAg) binding sites; both of these functions appear to be regulated by contents of the capsid. Cp can be targeted by antivirals - while self-assembly is the most accessible of Cp activities, we argue that it makes sense to engage the broader spectrum of Cp function. This article forms part of a symposium in Antiviral Research on "From the discovery of the Australia antigen to the development of new curative therapies for hepatitis B: an unfinished story." Copyright © 2015. Published by Elsevier B.V.
    No preview · Article · Jun 2015 · Antiviral research
Show more